Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
about
Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial.Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention.The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBSPrevention of atrial fibrillation: report from a national heart, lung, and blood institute workshopNon-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice.Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications.The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in manNovel approaches for pharmacological management of atrial fibrillation.Angiotensin II receptor blockers in the prevention of atrial fibrillation.Future directions in antiarrhythmic drug therapy for atrial fibrillation.Prerequisites for Exploring Predictors of Chronic Atrial Fibrillation Recurrence After AblationInefficacy interim monitoring procedures in randomized clinical trials: the need to report.Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction.2007 ESH‐ESC Guidelines for the management of arterial hypertension
P2860
Q31019192-1663F70E-82FB-4853-953D-88DE51D44EC9Q33724642-E45F268B-AE98-4F48-A0B7-1A934EBD02EEQ34607311-0E8DCB55-2480-4ECD-8F82-ACEB9D09B876Q36766941-F311C95F-934D-448F-862F-DEC514979F8EQ36853514-EF858333-B1AF-4906-91F3-9367A2F05066Q37083982-1F4B9D52-FABC-406E-A903-5226C7874A7EQ37101383-5BCAFFDC-8FA5-48B4-BD5D-433B68188907Q37109220-8D06386F-C74A-4C69-8A23-5123AEB4A04EQ37479070-BE8CD606-175D-4A98-8CE4-C8F7896D36FDQ37481193-3985B302-126E-4BB4-934C-7F6B5E7DD129Q37494662-E247CAE1-292E-4DE2-A3B5-B174183BD3E8Q37608547-8C2B2F12-F8BF-47AB-ADE2-44ED1F652E76Q38790555-32C2ADC7-DA6D-4BE7-A026-D2B90715F3E9Q39772400-AC22CA4B-AB2F-457F-BE65-2F9D4EA5DF07Q51891974-6D1FC3B3-8E37-48DA-8FFC-6C2935A3AAB9Q56970799-1A27005C-E972-4213-BDFD-4E24FB1A82A2
P2860
Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
description
im Januar 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2006
@uk
name
Rationale and design of the GI ...... atrial fibrillation recurrence
@en
Rationale and design of the GI ...... atrial fibrillation recurrence
@nl
type
label
Rationale and design of the GI ...... atrial fibrillation recurrence
@en
Rationale and design of the GI ...... atrial fibrillation recurrence
@nl
prefLabel
Rationale and design of the GI ...... atrial fibrillation recurrence
@en
Rationale and design of the GI ...... atrial fibrillation recurrence
@nl
P2093
P1476
Rationale and design of the GI ...... atrial fibrillation recurrence
@en
P2093
Gianni Tognoni
Giuseppe Di Pasquale
Lidia Staszewsky
Marcello Disertori
Maria Grazia Franzosi
Pietro Delise
Roberto Latini
P356
10.2459/01.JCM.0000199778.85343.08
P577
2006-01-01T00:00:00Z